Breast cancer risk associated with different HRT formulations: A register-based case-control study

BMC Women's Health

Volumn 6, Issue , 2006, Pages

  Dinger, Juergen C ^a   Heinemann, Lothar A J ^a   Möhner, Sabine ^a   Thai, Do Minh ^a   Assmann, Anita ^a  

^a Berlin Center for Epidemiology and Health Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIENOGEST; DYDROGESTERONE; ESTRADIOL; ESTRIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TIBOLONE;

ADULT; AGE; ARTICLE; BODY MASS; BREAST CANCER; CANCER CENTER; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG FORMULATION; DRUG UTILIZATION; EDUCATION; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; FEMALE; GERMANY; HORMONE SUBSTITUTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OVARY CANCER; RISK ASSESSMENT; SYSTEMATIC ERROR; TREATMENT DURATION; UTERUS CANCER;

EID: 33749186651     PISSN: 14726874     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-6-13     Document Type: Article

References (39)

1. Beckmann MW, Jap D, Huschel B, Dall P, Lux MP, Hanstein B, Bender HG: Wirkmechanismen ovarieller Steroidhormone und Antiöstrogene in der Karzinogenese der Mamma und des Endometrium. Geburth Frauenh 2000, 60:71-76.
2. Royal College of General Practitioners: Oral Contraception and health. An interim report from the oral contraceptive study of the RCGP. 1974. (Abstract)
3. Writing Group for the Women's Health Initiative Investigators: Risks and benefit of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288:321-333.
4. Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in Million Women Study. Lancet 2003, 362:419-27.
5. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR: Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Eng J Med 1980, 303:1195-98.
6. Genant HK, Baylink DJ, Gallagher JC, Harris ST, Steiger P, Herber M: Effects of estrogene sulfate on postmenopausal bon loss. Ostet Gynecol 1990, 76:579-84.
7. Gerhardsson de VM, London S: Reproductive factors, exogenous female hormones, and coloractal cancer by subsite. Cancer Causes Control 1992, 3:355-60.
8. Stampfer M, Colditz G: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47-63.
9. Grady D, Rueben SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016-37.
10. Windler E: Hormoneresatztherapie und kardiovaskuläre Prävention - Chance oder Risiko. J Menopause 2002, 10:32-40.
11. Prentice RL, Langer R, Stephanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J, from the Women's Health Initiative Investigators: Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative Clinical Trial. Am J Epidemiol 2005, 162:1-11.
12. ESHRE Capri Workshop Group: Hormones and breast cancer. Human Reproduction update 2004, 10:281-93.
13. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997, 350:1047-59.
14. Heinemann LAJ, Lewis MA, Kühl-Habich D, Braendle W, Garbe E, Möhner S: Lifetime history of oral contraceptive use and development of cancer of the uterus and ovary. Geburth Frauenheilk 2002, 62:566-573.
15. Heinemann LAJ, Lewis MA, Kühl-Habich D, Braendle W, Möhner S: The risk of breast tumors and lifetime history of oral contraceptive use. Geburth Frauenheilk 2002, 62:750-757.
16. Heinemann LAJ, Lewis MA, Kühl-Habich D, Braendle W, Möhner S: Use of oral contraceptives and risk of cancer of the uterus or ovary. Two case-control studies Geburth Frauenheilk 2003, 63:1018-26.
17. Heinemann LAJ, Assmann A, Lewis MA: How representative can be a cohort of volunteers for the general population? The German Cohort Study on Women' Health. Life and Medical Science Online 2001, 2: [http://www.lamso.com]. DOI:10.1072/LO203322 (11 pages)
18. Coulter A, Vessey M, McPherson K: The ability of women to recall their oral contraceptive histories. Contraception 1986, 33:T127-137.
19. Nischan P, Ebeling K, Thomas DB, Hirsch U: Comparison of recalled and validated oral contraceptive histories. Am J Epidemiol 1993, 138:697-703.
20. Hunter DJ, Manson JE, Colditz GA, Chason-Taber L, Troy L, Stampfer MJ, Speizer FE, Willet WC: Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 1997, 56:373-378.
21. American Institute for Cancer Research: Food, nutrition and the prevention of Cancer: a global perspective. Breast. World Cancer Research Fund and American Institute of Cancer Research, Washington (USA) DC:252-287. 20009 ISBN: 1 899533 05 2
22. Heinemann LAJ: WHI Studie und Million Women Study aus epidemiologischer Sicht. Frauenarzt 2004, 45:217-22.
23. Shapiro S: Risk of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003, 6:302-310.
24. Persson I: Cancer risk in women receiving estrogen-progestin replacement therapy. Maturitas 1996, 23(suppl):S37-S45.
25. Schneider HPG: HRT and cancer risk. separating fact from fiction. Maturitas 1999, 33:S65-S72.
26. The Women's Health Initiative Randomized controlled trial: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004, 291:1701-12.
27. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR: Relationship between long duration and different regimes of hormonal therapy and risk of breast cancer. JAMA 2003, 269:3254-63.
28. Jernstrom H, Bendahl PQ Lidfeldt J, Nerbrand C, Agardh CD, Samsioe G: A prospective study of different types of hormone replacement therapy use und the rsik fo subsequent breast cancer. The women's health in the Lund area (WHILA) study (Sweden). Cancer Cause Control 2003, 14:673-80.
29. Schuurman AG, van den Brandt PA, Goldbohm RA: Exoegnous hormone use and the risk of postmenopausal breast cancer: results from the Netherlands cohort study. Cancer Causes Control 1995, 6:416-24.
30. Wiseman RA: Breast cancer hypothesis: a single cause for the majority of cases. J Epidemiol Community Health 2000, 54(11):851-8.
31. Friedenson B, Friedenson H: Genetic testing for breast and ovarian cancer for women with a family history of breast cancer: weighing conflicting evidence about oral contraceptives. MedGenMed 2002, 4(3):3.
32. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH, Folsom AR: The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997, 127(11):973-80. Comment in: ACP J Club. 1998 May-Jun; 128(3):74
33. Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, Olson JE, Couch FJ, Anderson KE, Pankratz VS, Sellers TA: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000, 284(14):1837-8.
34. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F: Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2004, 114:448-54.
35. Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk. J Natl Cancer Inst 2000, 92:328-32.
36. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HQ, Persson I: Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Ant J Cancer 1999, 81:339-44.
37. Olsson HK, Ingyar C, Bladstro A: Hormone replacement therapy containing progestins and given continuously increases breast cancinoma risk in Sweden. Cancer 2003, 97:1387-92.
38. Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Ottensen B: Increased risk of breast cancer following different regimes of hormone replacement therapy frequently used in Europe. Int J Cancer 2004, 109:721-27.
39. Dietel M, Lewis MA, Shapiro S: Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini review. Human Reproduction 2005, 20:2052-60.